Abstract
More than a century after its first description through G.H. Whipple, the understanding of the chronic multisystemic infection called Whipple’s disease is still limited. However, within recent years the knowledge about diagnosis and treatment, the pathogenesis, and the biology of the agent itself have been improved by molecular biological and immunological methods. Despite the ubiquitous presence of the causative bacterium Tropheryma whipplei, Whipple’s disease is very rare, and immunogenetic host factors rather than the genotype of the agent influence the course of infection. Since the clinical features of classical Whipple’s disease are non-specific and the spectrum of isolated organ-specific manifestations might be underestimated, diagnosis often still is a challenge. Moreover, besides classical Whipple’s disease, there are newly recognized infections with T. whipplei, which do not fit in the concept of classical Whipple’s disease, for example, acute self-limiting infection and isolated T. whipplei endocarditis. Antibiotic therapy is usually successful. However, several problems are still unresolved, of which the most important are the following: which antibiotic should be used; how long treatment should be continued; how the immunoreconstitution inflammatory syndrome, which may occur after initiation of treatment, should be managed; and which is the best treatment of severe neurological manifestations.
Similar content being viewed by others
References
Whipple GH (1907) A hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids in the intestinal and mesenteric lymphatic tissues. Bull Johns Hopkins Hosp 18:382–393
Schneider T, Moos V, Loddenkemper C, Marth T, Fenollar F, Raoult D (2008) Whipple’s disease: new aspects of pathogenesis and treatment. Lancet Infect Dis 8(3):179–190
Lagier JC, Lepidi H, Raoult D, Fenollar F (2010) Systemic Tropheryma whipplei: clinical presentation of 142 patients with infections diagnosed or confirmed in a reference center. Medicine (Baltimore) 89(5):337–345
Raoult D, Fenollar F, Rolain JM et al (2010) Tropheryma whipplei in children with gastroenteritis. Emerg Infect Dis 16(5):776–782
Fenollar F, Trani M, Davoust B et al (2008) Prevalence of asymptomatic Tropheryma whipplei carriage among humans and nonhuman primates. J Infect Dis 197(6):880–887
Schoniger-Hekele M, Petermann D, Weber B, Muller C (2007) Tropheryma whipplei in the environment: survey of sewage plant influxes and sewage plant workers. Appl Environ Microbiol 73(6):2033–2035
Marth T, Kleen N, Stallmach A et al (2002) Dysregulated peripheral and mucosal Th1/Th2 response in Whipple’s disease. Gastroenterology 123(5):1468–1477
Moos V, Kunkel D, Marth T et al (2006) Reduced peripheral and mucosal Tropheryma whipplei-specific Th1 response in patients with Whipple’s disease. J Immunol 177(3):2015–2022
Moos V, Schmidt C, Geelhaar A et al (2010) Impaired immune functions of monocytes and macrophages in Whipple’s disease. Gastroenterology 138(1):210–220
Geelhaar A, Moos V, Schinnerling K et al (2010) Specific and nonspecific B-cell function in the small intestines of patients with Whipple’s disease. Infect Immun 78(11):4589–4592
Feurle GE, Junga NS, Marth T (2010) Efficacy of ceftriaxone or meropenem as initial therapies in Whipple’s disease. Gastroenterology 138(2):478–486
Fenollar F, Rolain JM, Alric L et al. (2009) Resistance to trimethoprim/sulfamethoxazole and Tropheryma whipplei. Int J Antimicrob Agents 34(3):255–259
Feurle GE, Marth T (1994) An evaluation of antimicrobial treatment for Whipple’s disease. Tetracycline versus trimethoprim-sulfamethoxazole. Dig Dis Sci 39(8):1642–1648
Panegyres PK (2008) Diagnosis and management of Whipple’s disease of the brain. Pract Neurol 8(5):311–317
Feurle GE, Moos V, Geelhaar A et al (2010) Immune reconstitution inflammatory syndrome in Whipple disease - an observational cohort study. Ann Intern Med 153:710–717
Paulley JW (1952) A case of Whipple’s disease (intestinal lipodystrophy). Gastroenterology 22(1):128–133
Cohen AS, Schimmel EM, Holt PR, Isselbacher KJ (1960) Ultrastructural abnormalities in Whipple’s disease. Proc Soc Exp Biol Med 105:411–414
Relman DA, Schmidt TM, MacDermott RP, Falkow S (1992) Identification of the uncultured bacillus of Whipple’s disease. N Engl J Med 327(5):293–301
Schoedon G, Goldenberger D, Forrer R et al (1997) Deactivation of macrophages with interleukin-4 is the key to the isolation of Tropheryma whippelii. J Infect Dis 176(3):672–677
Raoult D, Birg ML, La Scola B et al (2000) Cultivation of the bacillus of Whipple’s disease. N Engl J Med 342(9):620–625
La Scola B, Fenollar F, Fournier PE, Altwegg M, Mallet MN, Raoult D (2001) Description of Tropheryma whipplei gen. nov., sp. nov., the Whipple’s disease bacillus. Int J Syst Evol Microbiol 51(Pt 4):1471–1479
Dobbins WI (1987) Whipple’s disease. Charles C. Thomas, Springfield
Martinetti M, Biagi F, Badulli C et al. (2009) The HLA alleles DRB1*13 and DQB1*06 are associated to Whipple’s disease. Gastroenterology 136(7):2289–2294
Boulos A, Rolain JM, Mallet MN, Raoult D (2005) Molecular evaluation of antibiotic susceptibility of Tropheryma whipplei in axenic medium. J Antimicrob Chemother 55(2):178–181
Li W, Fenollar F, Rolain JM et al (2008) Genotyping reveals a wide heterogeneity of Tropheryma whipplei. Microbiology 154(Pt 2):521–527
Bentley SD, Maiwald M, Murphy LD et al (2003) Sequencing and analysis of the genome of the Whipple’s disease bacterium Tropheryma whipplei. Lancet 361(9358):637–644
Raoult D, Ogata H, Audic S et al (2003) Tropheryma whipplei Twist: a human pathogenic Actinobacteria with a reduced genome. Genome Res 13(8):1800–1809
Kowalczewska M, Villard C, Lafitte D, Fenollar F, Raoult D (2009) Global proteomic pattern of Tropheryma whipplei: a Whipple’s disease bacterium. Proteomics 9(6):1593–1616
Crapoulet N, Barbry P, Raoult D, Renesto P (2006) Global transcriptome analysis of Tropheryma whipplei in response to temperature stresses. J Bacteriol 188(14):5228–5239
Bonhomme CJ, Renesto P, Desnues B et al (2009) Tropheryma whipplei glycosylation in the pathophysiologic profile of Whipple’s disease. J Infect Dis 199(7):1043–1052
Raoult D, Fenollar F, Birg ML (2006) Culture of T. whipplei from the stool of a patient with Whipple’s disease. N Engl J Med 355(14):1503–1505
Rolain JM, Fenollar F, Raoult D (2007) False positive PCR detection of Tropheryma whipplei in the saliva of healthy people. BMC Microbiol 7:48
Bousbia S, Papazian L, Auffray JP et al (2010) Tropheryma whipplei in patients with pneumonia. Emerg Infect Dis 16(2):258–263
Fenollar F, Mediannikov O, Socolovschi C et al (2010) Tropheryma whipplei bacteremia during fever in rural West Africa. Clin Infect Dis 51(5):515–521
Fenollar F, Trape JF, Bassene H, Sokhna C, Raoult D (2009) Tropheryma whipplei in fecal samples from children, Senegal. Emerg Infect Dis 15(6):922–924
Escher R, Roth S, Droz S, Egli K, Altwegg M, Tauber MG (2010) Endocarditis due to Tropheryma whipplei: rapid detection, limited genetic diversity, and long-term clinical outcome in a local experience. Clin Microbiol Infect 16(8):1213–1222
Fenollar F, Lepidi H, Raoult D (2001) Whipple’s endocarditis: review of the literature and comparisons with Q fever, Bartonella infection, and blood culture-positive endocarditis. Clin Infect Dis 33(8):1309–1316
Mallmann C, Siemoneit S, Schmiedel D et al (2010) Fluorescence in situ hybridization to improve the diagnosis of endocarditis: a pilot study. Clin Microbiol Infect 16(6):767–773
Geissdorfer W, Wittmann I, Rollinghoff M, Schoerner C, Bogdan C (2001) Detection of a new 16 S-23 S rRNA spacer sequence variant (type 7) of Tropheryma whippelii in a patient with prosthetic aortic valve endocarditis. Eur J Clin Microbiol Infect Dis 20(10):762–763
Mahnel R, Kalt A, Ring S, Stallmach A, Strober W, Marth T (2005) Immunosuppressive therapy in Whipple’s disease patients is associated with the appearance of gastrointestinal manifestations. Am J Gastroenterol 100(5):1167–1173
Durand DV, Lecomte C, Cathebras P, Rousset H, Godeau P (1997) Whipple disease. Clinical review of 52 cases. The SNFMI Research Group on Whipple Disease. Societe Nationale Francaise de Medecine Interne. Med Baltim 76(3):170–184
Gerard A, Sarrot-Reynauld F, Liozon E et al (2002) Neurologic presentation of Whipple disease: report of 12 cases and review of the literature. Med Baltim 81(6):443–457
Pruss H, Katchanov J, Zschenderlein R, Loddenkemper C, Schneider T, Moos V (2007) A patient with cerebral Whipple disease with gastric involvement but no gastrointestinal symptoms: a consequence of local protective immunity? J Neurol Neurosurg Psychiatry 78(8):896–898
von Herbay A, Maiwald M, Ditton HJ, Otto HF (1996) Histology of intestinal Whipple’s disease revisited. A study of 48 patients. Virchows Arch 429(6):335–343
von Herbay A, Ditton HJ, Maiwald M (1996) Diagnostic application of a polymerase chain reaction assay for the Whipple’s disease bacterium to intestinal biopsies. Gastroenterology 110(6):1735–1743
Fenollar F, Laouira S, Lepidi H, Rolain JM, Raoult D (2008) Value of Tropheryma whipplei quantitative polymerase chain reaction assay for the diagnosis of Whipple disease: usefulness of saliva and stool specimens for first-line screening. Clin Infect Dis 47(5):659–667
Bakkali N, Fenollar F, Biswas S, Rolain JM, Raoult D (2008) Acquired resistance to trimethoprim-sulfamethoxazole during Whipple disease and expression of the causative target gene. J Infect Dis 198(1):101–108
Baisden BL, Lepidi H, Raoult D, Argani P, Yardley JH, Dumler JS (2002) Diagnosis of Whipple disease by immunohistochemical analysis: a sensitive and specific method for the detection of Tropheryma whipplei (the Whipple bacillus) in paraffin-embedded tissue. Am J Clin Pathol 118(5):742–748
Kowalczewska M, Fenollar F, Lafitte D, Raoult D (2006) Identification of candidate antigen in Whipple’s disease using a serological proteomic approach. Proteomics 6(11):3294–3305
Bonhomme CJ, Renesto P, Nandi S, Lynn AM, Raoult D (2008) Serological microarray for a paradoxical diagnostic of Whipple’s disease. Eur J Clin Microbiol Infect Dis 27(10):959–968
Fenollar F, Amphoux B, Raoult D (2009) A paradoxical Tropheryma whipplei western blot differentiates patients with Whipple disease from asymptomatic carriers. Clin Infect Dis 49(5):717–723
Keinath RD, Merrell DE, Vlietstra R, Dobbins WO 3rd (1985) Antibiotic treatment and relapse in Whipple’s disease. Long-term follow-up of 88 patients. Gastroenterology 88(6):1867–1873
Lagier JC, Fenollar F, Lepidi H, Raoult D (2010) Failure and relapse after treatment with trimethoprim/sulfamethoxazole in classic Whipple’s disease. J Antimicrob Chemother 65(9):2005–2012
Cannon WR (2003) Whipple’s disease, genomics, and drug therapy. Lancet 361(9372):1916
Schneider T, Stallmach A, von Herbay A, Marth T, Strober W, Zeitz M (1998) Treatment of refractory Whipple disease with interferon-gamma. Ann Intern Med 129(11):875–877
Lagier JC, Fenollar F, Lepidi H, Liozon E, Raoult D (2010) Successful treatment of immune reconstitution inflammatory syndrome in Whipple’s disease using thalidomide. J Infect 60(1):79–82
Pauletti C, Pujia F, Accorinti M et al (2010) An atypical case of neuro-Whipple: Clinical presentation, magnetic resonance spectroscopy and follow-up. J Neurol Sci 297(1–2):97–100
Panegyres PK, Edis R, Beaman M, Fallon M (2006) Primary Whipple’s disease of the brain: characterization of the clinical syndrome and molecular diagnosis. QJM 99(9):609–623
Thwaites GE, Nguyen DB, Nguyen HD et al (2004) Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 351(17):1741–1751
Raoult D, Lepidi H, Harle JR (2001) Tropheryma whipplei circulating in blood monocytes. N Engl J Med 345(7):548
Kalt A, Schneider T, Ring S et al (2006) Decreased levels of interleukin-12p40 in the serum of patients with Whipple’s disease. Int J Colorectal Dis 21(2):114–120
Al Moussawi K, Ghigo E, Kalinke U, Alexopoulou L, Mege JL, Desnues B (2010) Type I interferon induction is detrimental during infection with the Whipple’s disease bacterium, Tropheryma whipplei. PLoS Pathog 6(1):e1000722
Desnues B, Raoult D, Mege JL (2005) IL-16 is critical for Tropheryma whipplei replication in Whipple’s disease. J Immunol 175(7):4575–4582
Ghigo E, Barry AO, Pretat L et al (2010) IL-16 promotes T. whipplei replication by inhibiting phagosome conversion and modulating macrophage activation. PLoS ONE 5(10):e13561
Acknowledgement
This work was supported by EU Contract No. QLG1-CT-2002-01049 and the Deutsche Forschungs Gemeinschaft KFO 104 and SFB 633.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moos, V., Schneider, T. Changing paradigms in Whipple’s disease and infection with Tropheryma whipplei . Eur J Clin Microbiol Infect Dis 30, 1151–1158 (2011). https://doi.org/10.1007/s10096-011-1209-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-011-1209-y